Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampion efficacy in severe knee osteoarthritis
NCT03182686Phase 3Completed
- Sponsor
- Ampio Pharmaceuticals, Inc.
- Start
- Jun 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of aspartyl-alanyl-diketopiperazine in osteoarthritis (OA), sponsored by Ampio Pharmaceuticals, Inc.. Started Jun 2017; status: completed.
02
Drugs
aspartyl-alanyl-diketopiperazine
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03182686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03182686.